Tablet
IRBESARTAN HCT ACTAVIS TABLETS 150/12.5MG
Summary
IRBESARTAN HCT ACTAVIS TABLETS 150/12.5MG — Tablet containing hydrochlorothiazide, irbesartan. Hong Kong Registration No. HK-63378. Certificate Holder: TEVA PHARMACEUTICAL HONG KONG O/B TEVA PHARMACEUTICAL HONG KONG LIMITED. Date of Registration: 05 Jan, 2015.
Product NameIRBESARTAN HCT ACTAVIS TABLETS 150/12.5MG
Registration No.HK-63378
Certificate HolderTEVA PHARMACEUTICAL HONG KONG O/B TEVA PHARMACEUTICAL HONG KONG LIMITED
Holder AddressFLAT/RM 2303, 23/F, MIRA PLACE TOWER A, 132 NATHAN ROAD, TSIM SHA TSUI, KOWLOON
Ingredientshydrochlorothiazide, irbesartan
Dosage FormTablet
Legal ClassificationPart 1, Schedule 1 & Schedule 3 Poison
Sale RequirementPrescription only Medicines
Date of Registration05 Jan, 2015
ATC codesC03AA03, C09CA04
ATC Classification
ATC level 1
C Cardiovascular System
All ATC groupsC03, C09
This product contains more than one active ingredient. The ATC groups above describe the ingredients, not a single category for the product as a whole.
本頁為藥物資料查詢工具，並非藥物廣告、推廣或醫療建議。所有資料取自香港特別行政區衞生署藥物辦公室之公開資料，僅供參考；一切以藥物辦公室官方公布為準。 本頁不提供任何療效、適應症或治療用途之陳述。用藥前請諮詢醫生或註冊藥劑師。 本網站遵守香港法例第 231 章《不良廣告（醫藥）條例》之規管。